Overview of Acute/Chronic GVHD

Mikkael A. Sekeres MD, MS, further discussed the approval of imetelstat for the treatment of patients with low- to intermediate-1 risk myelodysplastic syndromes.

Zanubrutinib treatment resulted in £599,000 cost savings and 3.7 QALY savings compared with acalabrutinib for 1000 hypothetical patients.

During a Case-Based Roundtable® event, Amer Zeidan, MBBS, discussed how he would have approached a patient with anemia from low-risk myelodysplastic syndrome before the development of newer drugs in the first article of a 2-part series.

In general, mutations can occur in several genes in cytologically normal AML cells, including NPM1, FLT3, CEBPA, MLL, NRAS.

Secondary malignancies following CAR T-cell therapy have been a known risk, but an FDA investigation and call for labeling change have renewed interest.

The FDA granted a rare pediatric disease designation to a promising new drug, SLS009, for the treatment of pediatric leukemia.